Andreas Muehler
Immunic AG · Immunic Therapeutics
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andreas Muehler as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:15 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03846219 · MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)Immunic AG · active not recruiting · Relapsing-Remitting Multiple Sclerosis (RRMS) · study director
- Ph2NCT03341962 · Phase 2 Dose-finding IMU-838 for Ulcerative ColitisImmunic AG · terminated · Ulcerative Colitis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:15 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.Eur J Drug Metab Pharmacokinet · 202028 citationsRCR 1.3
- The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.Drugs R D · 201925 citationsRCR 1.0
- A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis.Ann Clin Transl Neurol · 202223 citationsRCR 1.8
- Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.Clin Pharmacol Drug Dev · 202318 citationsRCR 1.6
- Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.Lancet Gastroenterol Hepatol · 202518 citationsRCR 6.2
- Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.Invest New Drugs · 201815 citationsRCR 0.8
- Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial.Neurol Neuroimmunol Neuroinflamm · 202414 citationsRCR 2.0
- Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.J Clin Pharmacol · 20192 citationsRCR 0.1
- Vidofludimus Calcium in Patients With Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial.Clin Transl Gastroenterol · 20250 citationsRCR 0.0